Tell us about your search experience on the TGA website - complete our short survey
Sertraline and microscopic colitis
Medicines Safety Update
Published
Health professionals are advised that the Product Information (PI) documents for sertraline have been updated to include microscopic colitis as a potential adverse effect of unknown frequency based on post-marketing experience.
Sertraline is a selective serotonin reuptake inhibitor (SSRI) marketed in Australia under the brand name Zoloft and multiple generic brands. It is indicated for:
- children and adolescents (aged 6 years and over)
- treatment of obsessive compulsive disorder (OCD)
- adults
- treatment of major depression, OCD and panic disorder
- treatment of social phobia (also called social anxiety disorder) and prevention of its relapse
- treatment of premenstrual dysphoric disorder (PMDD) as defined by DSM-IV criteria.
Microscopic colitis is now included in the list of 'Gastrointestinal disorders' in the 'Adverse effects (Post-marketing experience)' section in Australian sertraline PI documents.
Microscopic colitis is a type of inflammatory bowel disease. It is characterised by non-bloody, watery diarrhoea. Other symptoms may include faecal urgency, incontinence and nocturnal episodes.
There are two different types of microscopic colitis - lymphocytic colitis and collagenous colitis. They present with the same symptoms but differences are found on histological examination. Diagnosis requires a biopsy.
Similar information about microscopic colitis has been added to product information in Europe based on a recommendation from the European Medicines Agency after reviewing pharmacovigilance data and the medical literature.
Cases in Australia
To 20 May 2021, there are six cases of microscopic colitis suspected to be related sertraline reported to the TGA and included in our Database of Adverse Event Notifications (DAEN). Of these, five were described as lymphocytic colitis1 and one as collagenous colitis.
When to be concerned?
Diarrhoea is listed as a very common adverse reaction associated with sertraline and occurs in at least 10% of people who start taking the medicine. If diarrhoea is severe or prolonged, microscopic colitis should be taken into consideration.
See the latest PI documents for sertraline products for further information.
Reference
| [1] | Menon R, Ng C. Sertraline-induced microscopic colitis. Psychosomatics. 2015 May-Jun;56(3):316-7. doi: 10.1016/j.psym.2014.03.008. Epub 2014 Mar 27. |
|---|
What to report? You don't need to be certain, just suspicious!
The TGA encourages the reporting of all suspected adverse reactions to medicines, including vaccines, over-the-counter medicines, herbal, traditional or alternative remedies.
We particularly request reports of:
- all suspected reactions to new medicines (look for the Black Triangle in PI and CMI documents - this symbol identifies medicines that are new or being used differently)
- all suspected medicines interactions
- suspected reactions causing death, admission to hospital or prolongation of hospitalisation, increased investigations or treatment, or birth defects.
Reports may be submitted:
- online at www.tga.gov.au
- by fax to 02 6232 8392
- by email to ADR.Reports@tga.gov.au
For more information about reporting, visit www.tga.gov.au or contact the TGA's Pharmacovigilance and Special Access Branch ADR.Reports@tga.gov.au.
Disclaimer
Medicines Safety Update is aimed at health professionals. It is intended to provide practical information to health professionals on medicine safety, including emerging safety issues. The information in Medicines Safety Update is necessarily general and is not intended to be a substitute for a health professional's judgment in each case, taking into account the individual circumstances of their patients. Reasonable care has been taken to ensure that the information is accurate and complete at the time of publication. The Australian Government gives no warranty that the information in this document is accurate or complete, and shall not be liable for any loss whatsoever due to negligence or otherwise arising from the use of or reliance on this document.
© Commonwealth of Australia 2021
This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to tga.copyright@tga.gov.au.
For the latest safety information from the TGA, subscribe to the TGA Safety Information email list via the TGA website.
For correspondence or further information about Medicines Safety Update, contact the TGA's Pharmacovigilance and Special Access Branch at ADR.Reports@tga.gov.au.
Medicines Safety Update is written by staff from the Pharmacovigilance and Special Access Branch.
Acting Editor: Dr Catherine Brogan
Deputy Editor: Mr Michael Pittman
Contributor: Ms Renae Mura and Dr Fiona Mackinnon
Topics
Related content
- Clindamycin capsules and injections - acute kidney injuryMedicines Safety Update - Information for health professionals
- Erenumab and hypertensionMedicines Safety Review
- Pentosan polysulfate sodium and pigmentary maculopathyHealth professionals are advised that the Product Information for pentosan polysulfate sodium has been updated with a warning about potential pigmentary maculopathy, especially after long-term use.